Skip to main content

Table 2 Dose-effect relationships of isomorellin, forbesione and doxorubicin combinations in cholangiocarcinoma cell lines

From: Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines

Cell line

Single compounds, drug & combinations

Parameter

CI value

DRI value

  

r

IC50

IC75

IC90

IC50

IC75

IC90

KKU-M156

Isomorellin

0.86

   

29.65

53.54

96.69

Doxorubicin

0.91

   

1.12

2.18

4.23

(D)1 + (D)2 (1 : 1.25)

0.97

0.92

0.47

0.24

   

KKU-100

Forbesione

0.88

   

4.46

8.32

15.51

Doxorubicin

0.88

   

1.00

1.73

2.99

(D)1 + (D)2 (1 : 0.25)

0.98

1.21

0.69

0.39

   

KKU-M139

Isomorellin

0.93

   

2.15

1.89

1.66

Doxorubicin

0.94

   

3.04

2.57

2.17

(D)1 + (D)2 (2 : 1)

0.81

0.80

0.92

1.06

   

Forbesione

0.89

   

3.28

2.83

2.44

Doxorubicin

0.89

   

6.57

5.20

4.12

 

(D)1 + (D)2 (2 : 1)

0.85

0.46

0.55

0.65

   
  1. Dose-effect relationships calculated using the median-effect equation. The r linear correlation is the coefficient of the median effect plot (indicates conformity of data). CIs were calculated using Chou and Talalay’s CI equation. The DRI dose reduction index was measured by comparing doses required to reach a given degree of inhibition when using compound(s) or drug as a single agent and/or in combination.